NewLink Genetics Corporation

Quick facts

Phase 3 pipeline

• HyperAcute-Pancreas Immunotherapy · Oncology
  HyperAcute-Pancreas is an immunotherapy that activates the patient's immune system to recognize and attack pancreatic cancer cells by combining a tumor-associated antigen vaccine with an immune checkpoint inhibitor.

Phase 1 pipeline

• Drug: Hyperacute Lung Cancer Cell Vaccine
• HyperAcute-Melanoma Vaccine
• HyperAcute-Pancreatic Cancer Vaccine
• HyperAcute-Prostate Cancer Vaccine
• Indoximod base formulation
• Indoximod Freebase
• Indoximod HCL F1
• Indoximod HCL F2
• NLG802

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• NewLink Genetics Corporation portfolio CI brief
• NewLink Genetics Corporation pipeline updates RSS